Insmed (NASDAQ:INSM) Shares Gap Down – Should You Sell?

Shares of Insmed, Inc. (NASDAQ:INSM) gapped down prior to trading on Monday. The stock had previously closed at $111.12, but opened at $105.50. Insmed shares last traded at $103.7520, with a volume of 566,631 shares.

Trending Headlines about Insmed

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Insmed reaffirmed 2026 revenue guidance of $1.7 billion to $1.9 billion, a range that includes the approximately $1.8 billion analyst consensus. The outlook covers expected sales performance for Brinsupri and Arikayce, reducing concerns about an immediate deterioration in operating expectations. Insmed Announces CFO Transition
• Neutral Sentiment: Insmed said CFO Sara Bonstein will step down effective October 30, 2026, after nearly seven years with the company. The company has not indicated that the transition changes its financial guidance, and investors will watch for details on her successor and the transition process. Insmed Announces CFO Transition
• Negative Sentiment: The unexpected CFO exit unsettled investors and raised concerns about leadership continuity, financial oversight and the company’s ability to execute its growth plans. Multiple reports attributed the stock’s decline to Bonstein’s departure, even though Insmed maintained its 2026 sales forecast. INSM Stock Slides on CFO Exit

Wall Street Analyst Weigh In

INSM has been the topic of a number of research reports. HC Wainwright reiterated a “buy” rating on shares of Insmed in a report on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Insmed in a research note on Friday, July 17th. Wells Fargo & Company increased their price target on Insmed from $161.00 to $169.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Barclays cut their price target on Insmed from $237.00 to $207.00 and set an “overweight” rating for the company in a report on Wednesday, September 30th. Finally, The Goldman Sachs Group assumed coverage on Insmed in a report on Thursday, September 24th. They set a “buy” rating and a $188.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $200.57.

Insmed Price Performance

The firm has a market capitalization of $22.98 billion, a P/E ratio of -25.60 and a beta of 0.83. The company has a 50-day moving average price of $120.21 and a 200-day moving average price of $120.60. The company has a debt-to-equity ratio of 0.74, a quick ratio of 3.40 and a current ratio of 3.72.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.61. The business had revenue of $425.49 million for the quarter, compared to the consensus estimate of $395.50 million. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. Insmed’s revenue for the quarter was up 296.1% on a year-over-year basis. During the same period last year, the company posted ($1.70) EPS. On average, sell-side analysts predict that Insmed, Inc. will post -1.84 earnings per share for the current year.

Insider Activity at Insmed

In other Insmed news, CEO William Lewis sold 10,699 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $117.40, for a total value of $1,256,062.60. Following the completion of the transaction, the chief executive officer directly owned 259,058 shares in the company, valued at $30,413,409.20. This trade represents a 3.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 239,850 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $133.27, for a total value of $31,964,809.50. Following the transaction, the chief operating officer owned 98,744 shares in the company, valued at approximately $13,159,612.88. This trade represents a 70.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 275,549 shares of company stock valued at $36,320,872. Insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Insmed

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Reflection Asset Management bought a new stake in shares of Insmed during the 4th quarter valued at about $30,000. CX Institutional acquired a new position in Insmed in the third quarter valued at approximately $46,000. Harbor Investment Advisory LLC bought a new position in shares of Insmed during the 2nd quarter worth approximately $52,000. Whittier Trust Co. of Nevada Inc. grew its position in shares of Insmed by 86.6% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 444 shares of the biopharmaceutical company’s stock worth $73,000 after buying an additional 206 shares during the period. Finally, Versant Capital Management Inc grew its position in shares of Insmed by 118.9% during the 3rd quarter. Versant Capital Management Inc now owns 648 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 352 shares during the period.

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options.

Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients.